查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2042704

Valsartan全球市場：按產品類型、適應症、劑型、劑量、分銷管道和地區進行分析—市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Valsartan Market: Analysis By Product Type, Indication, Formulation, Dosage Strength, Distribution Channel, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 220 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球Valsartan市場正處於強勁成長軌道，反映出全球心血管疾病負擔日益加重以及消費者對經濟實惠的學名藥的需求不斷成長。預計到2025年，市場規模將達到約15.4578億美元，到2035年將達到約31.8429億美元。這意味著在2026年至2035年的預測期內，複合年成長率約為7.50%，顯示市場將持續成長，並受到結構性因素的支撐，而非短期週期性波動。

這一成長主要受全球高血壓和心臟衰竭衰竭盛行率不斷上升的驅動，導致需要長期抗高血壓治療的患者群體持續擴大。由於Valsartan被廣泛用作第一線血管收縮素II受體阻斷劑（ARB），其需求與肥胖、糖尿病、久坐不動的生活方式和老齡化等生活方式相關危險因素的日益增多密切相關。

顯著的市場趨勢

全球Valsartan市場日益被少數幾家大規模垂直整合的製藥公司所主導，這些公司控制著大部分原料藥（API）和最終產品（FDF）的生產。這種市場力量的集中使得這些公司能夠對定價、供應鏈和全球分銷網路施加強大的影響力，而小規模的企業則在規模、合規性和成本效益方面難以與之競爭。

諾華作為一家Valsartan藥物研發公司，憑藉自有品牌產品代文（Diovan）和沙庫巴曲/Valsartan組合藥物恩瑞斯托（Entresto），繼續在高價值品牌藥領域保持領先地位。梯瓦製藥憑藉其廣泛的國際分銷網路和豐富的學名藥產品組合，仍然是全球Valsartan供應鏈中最具影響力的公司之一。

魯賓有限公司（Lupin Limited）憑藉其在受監管和準受監管市場中積極的擴大策略，正崛起為Valsartan市場的強勁挑戰者。奧羅賓多製藥（Aurobindo Pharma）是Valsartan市場最大的供應商之一。該公司以其激進的定價策略和強大的後向整合能力而聞名，這使其能夠掌控原料採購並顯著降低生產成本。

關鍵成長要素

高血壓在全球極高的盛行率和慢性病特徵，使其成為Valsartan市場長期需求的主要結構性促進因素。世界衛生組織（WHO）預測，到2024年，全球30至79歲的成年人中將有約14億人患有高血壓，約佔全球全球人口的三分之一。這種廣泛的疾病負擔導致需要終身服用降血壓藥的患者群體龐大且持續成長，而Valsartan仍然是其中最常用的血管收縮素II受體阻斷劑（ARB）之一。

新機會的趨勢

Entresto的上市將成為Valsartan市場最重要的需求催化劑之一。這主要是由於諾華公司重磅心臟衰竭治療藥物Entresto的專利將於2025年7月到期，預計屆時市場動態將會轉變。 Entresto是沙庫巴曲和Valsartan的複方製劑，一直是全球高價值血管張力素II受體拮抗劑（ARB）類藥物銷售的主要動力。其專利保護期的結束預計將從根本上重塑Valsartan產品的競爭格局和潛在需求結構。

最佳化障礙

強制性風險評估引入了一項重要的監管要求，預計將在一定程度上抑制Valsartan市場的成長，尤其是在學名藥領域。目前的監管要求所有簡略新藥申請（ANDA）提交者都必須提交詳細且全面的風險評估報告，評估生產過程中每個階段可能產生的亞硝胺雜質。這項要求反映了全球範圍內，在包括Valsartan在內的血管收縮素II受體阻斷劑（ARB）類藥物過去曾出現污染問題後，監管機構加強了對該類藥物的審查。

目錄

第1章摘要整理：全球Valsartan市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球Valsartan市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 全球高血壓與心血管疾病負擔展望
    • 監管情況（FDA、EMA、USP/EP亞硝胺標準、Entresto專利到期）
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：依產品類型

第4章：全球Valsartan市場分析

  • 競爭對手儀表板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球Valsartan市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 依產品類型
      • 關鍵見解
        • ValsartanAPI
        • 成品劑型（FDF）
          • 藥片
          • 固定劑量組合藥物
    • 配方
      • 關鍵見解
        • 單藥治療
        • 組合配方
    • 按劑量強度
      • 關鍵見解
        • 80毫克或更少
        • 81～160 mg
        • 超過160毫克
    • 適應症
      • 關鍵見解
        • 高血壓
        • 心臟衰竭
        • 心肌梗塞後
        • 其他心血管疾病
    • 透過分銷管道
      • 關鍵見解
        • 零售藥房
        • 醫院藥房
        • 網路藥房
        • 其他頻道
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 韓國
          • 澳洲和紐西蘭
          • ASEAN
            • 柬埔寨
            • 印尼
            • 馬來西亞
            • 菲律賓
            • 新加坡
            • 泰國
            • 越南
            • 其他東南亞國協
          • 其他亞太國家
        • 中東和非洲
          • UAE
          • 沙烏地阿拉伯
          • 南非
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

  • Alembic Pharmaceuticals Limited
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Inc.
  • Hetero Labs Limited
  • Lupin Pharmaceuticals Ltd.
  • Mylan NV
  • Novartis AG
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • Zydus Cadila
  • Other Prominent Players

第12章附錄

簡介目錄
Product Code: AA05261784

The global valsartan market is on a strong upward growth trajectory, reflecting both the rising global burden of cardiovascular diseases and the increasing reliance on cost-effective generic therapies. In 2025, the market was valued at approximately USD 1,545.78 million, and it is projected to reach around USD 3,184.29 million by 2035. This represents a compound annual growth rate (CAGR) of about 7.50% over the forecast period from 2026 to 2035, indicating sustained and structurally supported expansion rather than short-term cyclical growth.

This growth is primarily driven by the escalating prevalence of hypertension and heart failure worldwide, which continues to expand the patient pool requiring long-term antihypertensive treatment. As valsartan is widely used as a first-line angiotensin II receptor blocker (ARB), its demand remains closely linked to the rising incidence of lifestyle-related risk factors such as obesity, diabetes, sedentary behavior, and aging populations.

Noteworthy Market Developments

The global valsartan market is increasingly characterized by an oligopolistic structure dominated by a small group of large, vertically integrated pharmaceutical companies that control significant portions of both active pharmaceutical ingredient (API) production and finished dosage form (FDF) manufacturing. This concentration of market power allows these firms to exert strong influence over pricing, supply chains, and global distribution networks, while smaller players struggle to compete on scale, regulatory capacity, and cost efficiency.

Novartis, as the original innovator of valsartan through its branded product Diovan and the sacubitril/valsartan combination Entresto, continues to retain a presence in the high-value branded segment. Teva Pharmaceutical Industries remains one of the most influential players in the global valsartan supply chain, supported by its extensive international distribution network and diversified generics portfolio.

Lupin Limited has emerged as a strong challenger within the valsartan market, leveraging its aggressive expansion strategy in regulated and semi-regulated markets. Aurobindo Pharma stands out as one of the largest volume-driven suppliers in the valsartan market. The company is widely recognized for its aggressive pricing strategies and extensive backward integration capabilities, which enable it to control raw material sourcing and reduce production costs significantly.

Core Growth Drivers

Hypertension remains the primary structural driver of long-term demand in the valsartan market, supported by its extremely high global prevalence and chronic nature. According to the World Health Organization (WHO), approximately 1.4 billion adults aged 30-79 years were living with hypertension as of 2024, accounting for nearly one-third of the global population within that age group. This widespread disease burden creates a large and continuously expanding patient pool requiring lifelong antihypertensive therapy, of which valsartan remains one of the widely prescribed angiotensin II receptor blockers (ARBs).

Emerging Opportunity Trends

The Entresto pivot represents one of the most significant demand catalysts for the valsartan market, primarily due to the expected shift in market dynamics following the July 2025 patent expiry of Novartis's blockbuster heart failure therapy, Entresto. As a combination drug containing sacubitril and valsartan, Entresto has been a major driver of high-value ARB-related pharmaceutical revenues globally. Its loss of exclusivity is expected to fundamentally reshape both the competitive landscape and the underlying demand structure for valsartan-based products.

Barriers to Optimization

The risk assessment mandate has introduced a significant regulatory layer that is expected to moderately constrain the growth of the valsartan market, particularly within the generic drug segment. Under current regulatory expectations, every Abbreviated New Drug Application (ANDA) filer is required to submit a detailed and comprehensive risk assessment addressing the potential formation of nitrosamine impurities at each stage of the manufacturing process. This requirement reflects heightened global regulatory scrutiny following past contamination concerns in the angiotensin II receptor blocker (ARB) class, including valsartan.

Detailed Market Segmentation

By formulation, monotherapy products accounted for the largest share of the valsartan market in 2025, representing approximately 51% of total demand. This indicates that single-agent valsartan formulations continued to maintain a strong presence in clinical practice, despite the increasing shift toward combination therapies in modern hypertension management. Monotherapy formulations remain widely used due to their simplicity, ease of titration, and suitability for patients with mild to moderate hypertension or those newly diagnosed who require gradual treatment escalation.

By dosage strength, the 81-160 mg segment accounted for the highest share of the global valsartan market in 2025, contributing approximately 45% of total demand. This dominance reflects established clinical prescribing practices, where mid-range doses are most frequently used for long-term hypertension management. The concentration of demand within this dosage band highlights its role as the standard therapeutic range for maintaining stable blood pressure control in the majority of patients.

By indication, the hypertension segment accounted for the largest share of the global valsartan market in 2025, contributing approximately 52% of total market revenue. The segment's dominance is primarily attributed to the widespread prevalence of hypertension worldwide and the long-term nature of its treatment. As hypertension is one of the most common chronic cardiovascular disorders globally, the demand for antihypertensive medications such as valsartan continues to remain consistently high across both developed and emerging healthcare markets.

  • Based on product type, Finished Dosage Forms (FDFs) accounted for the largest share of the global valsartan market in 2025, contributing approximately 62% of total market revenue. This significant share highlights the growing importance of downstream pharmaceutical manufacturing activities, where companies derive greater value from producing and commercializing the final consumable drug product rather than solely supplying the active pharmaceutical ingredient (API). FDFs, which include tablets, capsules, and combination drug formulations, represent the stage at which pharmaceutical companies can establish stronger pricing power, brand recognition, and market presence.

Segment Breakdown

By Product Type

  • Valsartan API
  • Finished Dosage Forms (FDFs)
  • Tablets
  • Fixed-dose combinations

By Formulation

  • Monotherapy Formulations
  • Combination Formulations

By Dosage Strength

  • <= 80 mg
  • 81-160 mg
  • > 160 mg

By Indication

  • Hypertension
  • Heart Failure
  • Post-Myocardial Infarction
  • Other Cardiovascular Conditions

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Channels

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America accounted for the largest share of the global valsartan market in 2025, contributing approximately 38% of total market revenue. This leadership position was driven less by higher consumption volumes and more by the region's premium pharmaceutical pricing environment, particularly in the United States. Compared with many other regions where drug prices are regulated or subject to stricter reimbursement controls, the US market allows significantly higher pricing for branded cardiovascular therapies. As a result, revenue generation in North America remained disproportionately high relative to actual patient volume and prescription distribution.
  • A major factor behind this dominance was the continued commercial strength of Sacubitril/Valsartan, marketed as Entresto, which remained one of the most valuable cardiovascular drugs in the region during 2025. The product's strong adoption in the treatment of heart failure, combined with favorable reimbursement coverage and widespread physician acceptance in the US healthcare system, substantially elevated the overall valuation of the valsartan-related market segment. Consequently, North America's market share reflected not only the demand for standard valsartan formulations but also the exceptionally high revenue contribution from this premium combination therapy.

Leading Market Participants

  • Alembic Pharmaceuticals Limited
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Dr Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Inc.
  • Hetero Labs Limited
  • Lupin Pharmaceuticals Ltd.
  • Mylan N.V.
  • Novartis AG
  • Others
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Limited
  • Zydus Cadila
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Valsartan Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Valsartan Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Key Starting Material (KSM) Suppliers (OTBN, Sodium Azide)
    • 3.1.2. Active Pharmaceutical Ingredient (API) Manufacturers
    • 3.1.3. Excipient & Formulation Ingredient Providers
    • 3.1.4. Finished Dosage Form (FDF) & Generic Formulators
    • 3.1.5. Contract Manufacturing & Packaging Organizations (CMOs/CDMOs)
    • 3.1.6. Distributors, Wholesalers & Pharmacy Benefit Managers (PBMs)
    • 3.1.7. End Users (Hospitals, Retail Pharmacies, Online Pharmacies, Patients)
  • 3.2. Industry Outlook
    • 3.2.1. Global Hypertension & Cardiovascular Disease Burden Outlook
    • 3.2.2. Regulatory Landscape (FDA, EMA, USP/EP Nitrosamine Limits, Entresto Patent Cliff)
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Product Type

Chapter 4. Global Valsartan Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Valsartan Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Valsartan API
        • 5.2.1.1.2. Finished Dosage Forms (FDFs)
          • 5.2.1.1.2.1. Tablets
          • 5.2.1.1.2.2. Fixed-dose Combinations
    • 5.2.2. By Formulation
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Monotherapy Formulations
        • 5.2.2.1.2. Combination Formulations
    • 5.2.3. By Dosage Strength
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. <= 80 mg
        • 5.2.3.1.2. 81-160 mg
        • 5.2.3.1.3. > 160 mg
    • 5.2.4. By Indication
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Hypertension
        • 5.2.4.1.2. Heart Failure
        • 5.2.4.1.3. Post-Myocardial Infarction
        • 5.2.4.1.4. Other Cardiovascular Conditions
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Retail Pharmacies
        • 5.2.5.1.2. Hospital Pharmacies
        • 5.2.5.1.3. Online Pharmacies
        • 5.2.5.1.4. Other Channels
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. South Korea
          • 5.2.6.1.3.5. Australia & New Zealand
          • 5.2.6.1.3.6. ASEAN
            • 5.2.6.1.3.6.1. Cambodia
            • 5.2.6.1.3.6.2. Indonesia
            • 5.2.6.1.3.6.3. Malaysia
            • 5.2.6.1.3.6.4. Philippines
            • 5.2.6.1.3.6.5. Singapore
            • 5.2.6.1.3.6.6. Thailand
            • 5.2.6.1.3.6.7. Vietnam
            • 5.2.6.1.3.6.8. Rest of ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa
          • 5.2.6.1.4.1. UAE
          • 5.2.6.1.4.2. Saudi Arabia
          • 5.2.6.1.4.3. South Africa
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Product Type
      • 6.2.1.2. By Formulation
      • 6.2.1.3. By Dosage Strength
      • 6.2.1.4. By Indication
      • 6.2.1.5. By Distribution Channel
      • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Product Type
      • 7.2.1.2. By Formulation
      • 7.2.1.3. By Dosage Strength
      • 7.2.1.4. By Indication
      • 7.2.1.5. By Distribution Channel
      • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Product Type
      • 8.2.1.2. By Formulation
      • 8.2.1.3. By Dosage Strength
      • 8.2.1.4. By Indication
      • 8.2.1.5. By Distribution Channel
      • 8.2.1.6. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Product Type
      • 9.2.1.2. By Formulation
      • 9.2.1.3. By Dosage Strength
      • 9.2.1.4. By Indication
      • 9.2.1.5. By Distribution Channel
      • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Product Type
      • 10.2.1.2. By Formulation
      • 10.2.1.3. By Dosage Strength
      • 10.2.1.4. By Indication
      • 10.2.1.5. By Distribution Channel
      • 10.2.1.6. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Alembic Pharmaceuticals Limited
  • 11.2. AstraZeneca plc
  • 11.3. Aurobindo Pharma Limited
  • 11.4. Dr. Reddy's Laboratories Ltd.
  • 11.5. Glenmark Pharmaceuticals Inc.
  • 11.6. Hetero Labs Limited
  • 11.7. Lupin Pharmaceuticals Ltd.
  • 11.8. Mylan N.V.
  • 11.9. Novartis AG
  • 11.10. Sandoz International GmbH
  • 11.11. Sun Pharmaceutical Industries
  • 11.12. Teva Pharmaceutical Industries Ltd.
  • 11.13. Torrent Pharmaceuticals Limited
  • 11.14. Zydus Cadila
  • 11.15. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators